🇺🇸 FDA
Patent

US 11661593

Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

granted A61PA61P7/02A61P9/00

Quick answer

US patent 11661593 (Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof) held by Takeda Pharmaceutical Company Limited expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P7/02, A61P9/00